CA2882502A1 - Compositions and methods for treating celiac sprue disease - Google Patents

Compositions and methods for treating celiac sprue disease Download PDF

Info

Publication number
CA2882502A1
CA2882502A1 CA2882502A CA2882502A CA2882502A1 CA 2882502 A1 CA2882502 A1 CA 2882502A1 CA 2882502 A CA2882502 A CA 2882502A CA 2882502 A CA2882502 A CA 2882502A CA 2882502 A1 CA2882502 A1 CA 2882502A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
polypeptide
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2882502A
Other languages
English (en)
French (fr)
Inventor
Justin Siegel
David Baker
Sydney Rin Anna Gordon
Ingrid Swanson Pultz
Elizabeth Joy Stanley
Sarah Jane Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington Center for Commercialization
Original Assignee
University of Washington Center for Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington Center for Commercialization filed Critical University of Washington Center for Commercialization
Publication of CA2882502A1 publication Critical patent/CA2882502A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
CA2882502A 2011-08-10 2012-08-10 Compositions and methods for treating celiac sprue disease Pending CA2882502A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161521899P 2011-08-10 2011-08-10
US61/521,899 2011-08-10
PCT/US2012/050364 WO2013023151A2 (en) 2011-08-10 2012-08-10 Compositions and methods for treating celiac sprue disease

Publications (1)

Publication Number Publication Date
CA2882502A1 true CA2882502A1 (en) 2013-02-14

Family

ID=46690751

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2882502A Pending CA2882502A1 (en) 2011-08-10 2012-08-10 Compositions and methods for treating celiac sprue disease

Country Status (18)

Country Link
US (7) US9289473B2 (enExample)
EP (3) EP4023243A3 (enExample)
JP (5) JP6342802B2 (enExample)
CA (1) CA2882502A1 (enExample)
CY (1) CY1120877T1 (enExample)
DK (1) DK2718434T3 (enExample)
ES (2) ES2896489T3 (enExample)
HR (1) HRP20180687T1 (enExample)
HU (1) HUE037870T2 (enExample)
LT (1) LT2718434T (enExample)
NO (1) NO2718434T3 (enExample)
PL (2) PL3400958T3 (enExample)
PT (1) PT2718434T (enExample)
RS (1) RS57234B1 (enExample)
SI (1) SI2718434T1 (enExample)
SM (1) SMT201800249T1 (enExample)
TR (1) TR201806885T4 (enExample)
WO (1) WO2013023151A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2718434T (lt) 2011-08-10 2018-08-10 University Of Washington Through Its Center For Commercialization Kompozicijos ir būdai, skirti celiakijos gydymui
US10266815B2 (en) * 2013-08-14 2019-04-23 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
TN2017000520A1 (en) * 2015-06-08 2019-04-12 Univ California Compositions and methods for treating celiac sprue disease
US12655410B2 (en) 2016-12-22 2026-06-16 Ew Nutrition Gmbh Stable protease variants
MX2019007287A (es) * 2016-12-22 2019-09-27 Ew Nutrition Gmbh Variantes de proteasas estables.
WO2020087017A1 (en) * 2018-10-26 2020-04-30 The Regents Of The University Of California Use of proteolytic enzymes to enhance protein bioavailability
US20240226248A9 (en) * 2018-10-26 2024-07-11 The Regents Of The University Of California Methods and compositions for improving protein hydrolysis
US20250064903A1 (en) 2020-10-30 2025-02-27 University Of Washington Compositions and methods for treating celiac sprue disease
JP7900846B2 (ja) 2022-01-26 2026-08-05 ダイジェスティーバ・インコーポレイテッド 血糖安定化方法及び組成物
WO2025068987A1 (en) 2023-09-28 2025-04-03 Takeda Pharmaceutical Company Limited A method of producing a kumamolisin-as polypeptide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688229B1 (fr) 1992-03-09 1995-06-23 Ulice Soc Procede de synthese enzymatique d'esters alkyliques de peptides, produits ainsi obtenus et utilisation desdits produits.
JP2002078489A (ja) * 2000-09-04 2002-03-19 Daiwa Kasei Kk セリン残基が活性発現に関与する新規酸性プロテアーゼ
AU2003215272B2 (en) 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7265093B2 (en) 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7605150B2 (en) 2002-05-14 2009-10-20 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
ATE554392T1 (de) 2002-11-20 2012-05-15 Univ Leland Stanford Junior Diagnoseverfahren für sprue/zöliakie
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
EP1600141B1 (en) 2004-05-24 2013-04-17 3M Deutschland GmbH Collagenolytic active enzyme containing compositions for the treatment of dental caries
EP1726643A1 (en) * 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
NZ591025A (en) 2008-08-21 2013-01-25 Alvine Pharmaceuticals Inc Formulation for oral administration of proteins
LT2718434T (lt) 2011-08-10 2018-08-10 University Of Washington Through Its Center For Commercialization Kompozicijos ir būdai, skirti celiakijos gydymui
JP6203743B2 (ja) 2011-12-06 2017-09-27 フオンダツイオーネ・イステイトウート・インスブリコ・デイ・リチエルカ・ペル・ラ・ビータ アクチノミセス・アクチノアロムルス（ＡＣＴＩＮＯＭＹＣＥＴＥＡＣＴＩＮＯＡＬＬＯＭＵＲＵＳ）由来の、酸性ｐＨにてグルテンペプチドおよびタンパク質を加水分解できる新規プロテアーゼ
US10266815B2 (en) 2013-08-14 2019-04-23 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
TN2017000520A1 (en) 2015-06-08 2019-04-12 Univ California Compositions and methods for treating celiac sprue disease

Also Published As

Publication number Publication date
US20210085761A1 (en) 2021-03-25
EP4023243A2 (en) 2022-07-06
RS57234B1 (sr) 2018-07-31
JP2017221201A (ja) 2017-12-21
LT2718434T (lt) 2018-08-10
JP6502428B2 (ja) 2019-04-17
US10874720B2 (en) 2020-12-29
US9707280B2 (en) 2017-07-18
JP2014529399A (ja) 2014-11-13
SI2718434T1 (en) 2018-06-29
DK2718434T3 (en) 2018-07-09
EP3400958B1 (en) 2021-08-04
US20140178355A1 (en) 2014-06-26
US20160166656A1 (en) 2016-06-16
PT2718434T (pt) 2018-05-21
JP2024028452A (ja) 2024-03-04
JP2021094031A (ja) 2021-06-24
SMT201800249T1 (it) 2018-07-17
US9925249B2 (en) 2018-03-27
EP2718434A2 (en) 2014-04-16
NO2718434T3 (enExample) 2018-08-25
EP4023243A3 (en) 2022-09-14
HUE037870T2 (hu) 2018-09-28
EP2718434B1 (en) 2018-03-28
US10149892B2 (en) 2018-12-11
TR201806885T4 (tr) 2018-06-21
ES2896489T3 (es) 2022-02-24
US20240207376A1 (en) 2024-06-27
HRP20180687T1 (hr) 2018-06-15
PL3400958T3 (pl) 2022-01-03
US12544430B2 (en) 2026-02-10
ES2667418T3 (es) 2018-05-10
PL2718434T3 (pl) 2018-08-31
JP6342802B2 (ja) 2018-06-13
US20180185458A1 (en) 2018-07-05
US9289473B2 (en) 2016-03-22
CY1120877T1 (el) 2019-12-11
JP2019162107A (ja) 2019-09-26
EP3400958A1 (en) 2018-11-14
US20170296633A1 (en) 2017-10-19
US20190083585A1 (en) 2019-03-21
WO2013023151A2 (en) 2013-02-14
WO2013023151A3 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
US12544430B2 (en) Compositions and methods for treating celiac sprue disease
US20240158774A1 (en) Compositions and Methods for Treating Celiac Sprue Disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170809

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D156 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION SENT - EXAMINATION ON HOLD

Effective date: 20250121

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250121

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250513

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250514

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B309 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR CONTINUED EXAMINATION NOTICE

Effective date: 20250521

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251112

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260407

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20260521